Novo Nordisk A/S (NVO)

100.40 -1.44 (-1.41%) At close: 04:00PM EST

Novo Nordisk A/S

Novo Alle 1
Bagsvaerd 2880
Denmark
45 44 44 88 88
https://www.novonordisk.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 61,412

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. Lars Fruergaard Jorgensen	President, CEO & Member of Management Board	4.72M	N/A	1966
Mr. Karsten Munk Knudsen	Executive VP, CFO & Member of the Management Board	1.87M	N/A	1971
Mr. Henrik Ehlers Wulff	Executive VP of Product Supply, Quality & IT and Member of the Management Board	1.88M	N/A	1970
Ms. Camilla Sylvest	Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board	1.84M	N/A	1972
Dr. Martin Holst Lange	Executive VP of Development & Member of the Management Board	1.78M	N/A	1970
Dr. Marcus Schindler Ph.D.	EVP of Research & Early Development, Chief Scientific Officer & Member of the Management Board	1.78M	N/A	1966
Mr. Maziar Mike Doustdar	Executive VP of International Operations & Member of the Management Board	N/A	N/A	1970
Mr. Douglas J. Langa	Executive VP of North America Operations & Member of Management Board	N/A	N/A	1966
Mr. Ludovic Helfgott	Executive VP, Head of Rare Disease & Member of Management Board	N/A	N/A	1974
Ms. Tania Sabroe	Executive VP of Global People & Organisation and Member of Management Board	N/A	N/A	N/A

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Corporate Governance

Novo Nordisk A/S’s ISS Governance QualityScore as of December 1, 2023 is 2. The pillar scores are Audit: 2; Board: 3; Shareholder Rights: 9; Compensation: 1.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.